Our Faculty

Michael C. Heinrich, M.D.
Interim Division Head
Center For Health & Healing
Professor of Medicine

Specialty: Hematology and Medical Oncology

Lab Phone: (503) 220-8262 x 57081
E-mail: heinrich@ohsu.edu

Michael Heinrich M.D. is currently a Professor of Medicine at Oregon Health & Sciences University. He earned his medical degree in 1984 from Johns Hopkins School of Medicine in Baltimore and completed both his residency training and Hematology and Medical Oncology fellowship at OHSU. His primary research interest is in the development of novel tyrosine kinase inhibitors for treatment of human cancers. Dr. Heinrich's research includes both pre-clinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic.

• Rubin BP, Heinrich MC, Corless CL. Related Articles, LinksGastrointestinal stromal tumour. Lancet. 2007 May 19;369(9574):1731-41. Review. Erratum in: Lancet. 2007 Aug 4;370(9585):388. PMID: 17512858 [PubMed - indexed for MEDLINE]
• Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Related Articles, LinksEfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. PMID: 17046465 [PubMed - indexed for MEDLINE]
• Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC. Related Articles, LinksFLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006 Nov;20(11):2008-14. Epub 2006 Sep 14. PMID: 16990784 [PubMed - indexed for MEDLINE]
• Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA. Related Articles, LinksMolecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006 Oct 10;24(29):4764-74. Epub 2006 Sep 5. PMID: 16954519 [PubMed - indexed for MEDLINE]
• Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ. Related Articles, LinksActivating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006 Jul;10(1):65-75. PMID: 16843266 [PubMed - indexed for MEDLINE]
• Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ. Related Articles, LinksPhosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res. 2006 Sep;30(9):1097-104. Epub 2006 Feb 7. PMID: 16464493 [PubMed - indexed for MEDLINE]
• Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Related Articles, LinksDasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. PMID: 16397263 [PubMed - indexed for MEDLINE]
• Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. Related Articles, LinksMutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005 Sep;19:1536-42. PMID: 16015387 [PubMed - indexed for MEDLINE]

Search PubMed for more publications